Early days yet but hopefully with the help of Edwards will lead to new products for treating heart valve problems .
From 2nd Quarter Report Edwards LifeSciences July 29 2021Transcatheter Mitral and Tricuspid Therapies (TMTT)
Edwards progressed during the quarter in the enrollment of five pivotal trials across the company's differentiated portfolio of technologies to support patients suffering from mitral and tricuspid regurgitation. The company continues to build a body of compelling clinical evidence reinforced by data presented at recent medical meetings.
Second quarter TMTT sales were $22 million, driven by continued adoption of PASCAL as the company activated more centers across Europe.
Edwards continues to estimate the global TMTT opportunity will triple to approximately $3 billion by 2025 and remains committed to transforming the treatment of patients with mitral and tricuspid valve disease around the world.
Early days yet but hopefully with the help of Edwards will lead...
Add EIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.015(12.0%) |
Mkt cap ! $69.32M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.0¢ | 13.0¢ | $155.4K | 1.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 46623 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 72560 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
13.5¢ |
Change
0.015 ( 3.85 %) |
||||
| Open | High | Low | Volume | ||
| 13.0¢ | 14.0¢ | 13.0¢ | 244414 | ||
| Last updated 15.57pm 15/05/2024 ? | |||||
| EIQ (ASX) Chart |